Kalvista Historical Cash Flow

KALV Stock  USD 11.93  0.41  3.32%   
Analysis of Kalvista Pharmaceuticals cash flow over time is an excellent tool to project Kalvista Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 3.7 M or Depreciation of 126.3 K as it is a great indicator of Kalvista Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Kalvista Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kalvista Pharmaceuticals is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

About Kalvista Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Kalvista balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Kalvista's non-liquid assets can be easily converted into cash.

Kalvista Pharmaceuticals Cash Flow Chart

At this time, Kalvista Pharmaceuticals' Change In Cash is fairly stable compared to the past year. Stock Based Compensation is likely to climb to about 26.5 M in 2025, whereas Begin Period Cash Flow is likely to drop slightly above 3.7 M in 2025.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Kalvista Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Kalvista Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from Kalvista Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Kalvista Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.At this time, Kalvista Pharmaceuticals' Change In Cash is fairly stable compared to the past year. Stock Based Compensation is likely to climb to about 26.5 M in 2025, whereas Begin Period Cash Flow is likely to drop slightly above 3.7 M in 2025.

Kalvista Pharmaceuticals cash flow statement Correlations

0.3-0.050.59-0.63-0.3-0.440.110.210.050.380.450.190.480.010.07-0.020.710.570.140.34
0.3-0.870.470.160.40.070.22-0.540.010.320.710.280.010.44-0.14-0.130.530.11-0.14-0.1
-0.05-0.87-0.11-0.47-0.68-0.29-0.320.77-0.2-0.3-0.74-0.10.24-0.70.280.0-0.250.110.330.31
0.590.47-0.11-0.26-0.07-0.350.21-0.140.20.20.360.480.47-0.130.44-0.190.80.680.510.38
-0.630.16-0.47-0.260.780.40.52-0.70.570.110.15-0.16-0.560.480.23-0.13-0.35-0.570.1-0.29
-0.30.4-0.68-0.070.780.330.39-0.90.640.450.560.16-0.190.720.01-0.290.01-0.18-0.12-0.09
-0.440.07-0.29-0.350.40.330.16-0.320.06-0.160.18-0.3-0.610.69-0.030.26-0.53-0.35-0.14-0.43
0.110.22-0.320.210.520.390.16-0.360.610.10.3-0.45-0.430.450.660.170.0-0.310.54-0.3
0.21-0.540.77-0.14-0.7-0.9-0.32-0.36-0.55-0.32-0.7-0.30.17-0.680.060.15-0.23-0.040.150.13
0.050.01-0.20.20.570.640.060.61-0.550.490.340.05-0.010.440.49-0.250.070.070.390.24
0.380.32-0.30.20.110.45-0.160.1-0.320.490.570.530.520.35-0.06-0.80.420.23-0.150.69
0.450.71-0.740.360.150.560.180.3-0.70.340.570.380.090.74-0.17-0.170.610.31-0.220.07
0.190.28-0.10.48-0.160.16-0.3-0.45-0.30.050.530.380.75-0.14-0.28-0.690.680.7-0.240.74
0.480.010.240.47-0.56-0.19-0.61-0.430.17-0.010.520.090.75-0.41-0.18-0.60.610.76-0.140.85
0.010.44-0.7-0.130.480.720.690.45-0.680.440.350.74-0.14-0.41-0.070.07-0.06-0.19-0.2-0.3
0.07-0.140.280.440.230.01-0.030.660.060.49-0.06-0.17-0.28-0.18-0.070.0-0.01-0.10.970.03
-0.02-0.130.0-0.19-0.13-0.290.260.170.15-0.25-0.8-0.17-0.69-0.60.070.0-0.31-0.160.05-0.81
0.710.53-0.250.8-0.350.01-0.530.0-0.230.070.420.610.680.61-0.06-0.01-0.310.730.070.45
0.570.110.110.68-0.57-0.18-0.35-0.31-0.040.070.230.310.70.76-0.19-0.1-0.160.73-0.030.58
0.14-0.140.330.510.1-0.12-0.140.540.150.39-0.15-0.22-0.24-0.14-0.20.970.050.07-0.030.03
0.34-0.10.310.38-0.29-0.09-0.43-0.30.130.240.690.070.740.85-0.30.03-0.810.450.580.03
Click cells to compare fundamentals

Kalvista Pharmaceuticals Account Relationship Matchups

Kalvista Pharmaceuticals cash flow statement Accounts

202020212022202320242025 (projected)
Change In Cash(16.2M)34.8M(19.9M)25.5M(24.4M)52.3M
Stock Based Compensation7.1M11.1M9.9M21.9M25.2M26.5M
Free Cash Flow(30.3M)(79.1M)(76.5M)(89.7M)(80.7M)(76.7M)
Change In Working Capital8.3M(12.3M)7.4M15.2M17.4M18.3M
Begin Period Cash Flow32.0M15.8M50.6M30.7M56.2M3.7M
Other Cashflows From Financing Activities216K1.5M1.6M1.5M53.8M(1.1M)
Depreciation512K537K564K718K816K126.4K
Other Non Cash Items114K4.9M84K(485K)(557.8K)(529.9K)
Capital Expenditures220K82K931K1.2M443K491.4K
Total Cash From Operating Activities(44.8M)(30.2M)(78.1M)(75.3M)(89.2M)(21.9M)
Net Income(29.1M)(46.2M)(82.3M)(92.9M)(126.6M)(26.1M)
Total Cash From Financing Activities11.6M212.1M1.6M58.1M150.7M48.6M
End Period Cash Flow15.8M50.6M30.7M56.2M31.8M9.3M
Sale Purchase Of Stock11.6M212.1M1.6M58.1M78.3M41.2M
Total Cashflows From Investing Activities16.8M(147.7M)57.9M41.4M(1.2M)(1.3M)
Change To Account Receivables(4.9M)(5.8M)7.5M(5.2M)(2.3M)8.2M
Change To Operating Activities(6.9M)8.2M(14.0M)144K129.6K136.1K
Change To Netincome4.2M6.4M13.2M8.4M4.0M3.8M
Change To Liabilities(1.1M)1.1M2.2M3.0M32.2K30.6K
Investments17.0M(147.6M)58.8M42.6M(84.7M)(750.8K)
Cash And Cash Equivalents Changes(16.5M)34.3M(18.7M)24.3M44.8M47.1M
Cash Flows Other Operating(19.6M)7.3M(14.3M)4.5M(460K)(483K)
Other Cashflows From Investing Activities(68.3M)17.0M(147.7M)57.9M(443K)(679.3K)
Issuance Of Capital Stock210.6M0.056.6M96.9M87.3M61.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.